Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Gayle Barbara Duncan

Affiliations

  • Director at Atea Pharmaceuticals Inc. (AVIR), 2020-10-30
  • Director at Immunomedics Inc (IMMU), 2020-10-23
  • Director at Jounce Therapeutics Inc. (JNCE), 2020-09-16
  • Director at Adaptimmune Therapeutics Plc (ADAP), 2020-07-01
  • Director at Ovid Therapeutics Inc. (OVID), 2020-06-08
  • Director at Aevi Genomic Medicine Inc. (GNMX), 2020-02-05
  • Director at Innoviva Inc. (INVA), 2017-04-24
  • Chief Accounting Officer at Intercept Pharmaceuticals Inc (ICPT), 2016-10-06
Insider Trading: Purchases See All
Company Symbol Price Amount Relationship Remaining Holdings Date Form 4
GNMX $1.26 59,524 Director 59,524 2017-10-17 Filing
Insider Trading: Sales See All
Company Symbol Price Amount Relationship Remaining Holdings Date Form 4
JNCE $10.50 5,000 Director 0 2020-09-15 Filing
JNCE $9.50 5,000 Director 5,000 2020-09-15 Filing
JNCE $28.11 2,000 Director 0 2018-03-15 Filing
JNCE $25.00 4,000 Director 0 2018-01-26 Filing
ICPT $163.20 147 Officer 30,661 2016-10-03 Filing